Liraglutide 3.0 mg, the first GLP-1 RA used in the treatment of obesity, was approved by Food and Drug Administration (FDA) in 2014 and by European Medicines Agency (EMA) in 2015 [17]. The gene discussed is GLP1R; the disease is obesity disorder.